Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Buonsanti, Cecilia ^a   Balocchi, Cristiana ^a   Harfouche, Carole ^a   Corrente, Federica ^a   Galli Stampino, Luisa ^a   Mancini, Francesca ^a   Tontini, Marta ^a   Malyala, Padma ^b   Bufali, Simone ^a   Baudner, Barbara ^a   De Gregorio, Ennio ^a   Valiante, Nicholas M ^b,c   O'Hagan, Derek T ^b   Rappuoli, Rino ^a   D'Oro, Ugo ^a  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United States)

^c MODERNA THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CRM197 (NON-TOXIC VARIANT OF DIPHTHERIA TOXIN); GLYCOCONJUGATE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MENINGOCOCCUS VACCINE; TLR7 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 7; VACCINE;

ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; DRUG EFFECT; EPIDEMIC MENINGITIS; FEMALE; HUMAN; IMMUNOLOGY; MICROBIOLOGY; MOUSE; NEISSERIA MENINGITIDIS; VACCINATION; VACCINE IMMUNOGENICITY;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; FEMALE; GLYCOCONJUGATES; HUMANS; IMMUNOGENICITY, VACCINE; IMMUNOGLOBULIN G; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEISSERIA MENINGITIDIS; TOLL-LIKE RECEPTOR 7; VACCINATION; VACCINES, CONJUGATE;

EID: 84979266152     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29063     Document Type: Article

References (25)

1. De Gregorio, E. and Rappuoli, R. From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nature reviews. Immunology 14, 505-514, doi:10.1038/nri3694 (2014).
2. Trotter, C. L. et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 26, 4434-4445, doi:10.1016/j.vaccine.2008.05.073 (2008).
3. Costantino, P., Rappuoli, R. and Berti, F. The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opinion on Drug Discovery 6, 1045-1066, doi:10.1517/17460441.2011.609554 (2011).
4. Avci, F. Y. and Kasper, D. L. How bacterial carbohydrates influence the adaptive immune system. Annual Review of Immunology 28, 107-130, doi:10.1146/annurev-immunol-030409-101159 (2010).
5. Del Giudice, G., Fragapane, E., Della Cioppa, G. and Rappuoli, R. Aflunov (R): a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opinion on Biological Therapy 13, 121-135, doi:10.1517/14712598.2013.748030 (2013).
6. Pulendran, B. and Ahmed, R. Immunological mechanisms of vaccination. Nature Immunology 12, 509-517 (2011).
7. Vesikari, T. et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. The New England journal of Medicine 365, 1406-1416, doi:10.1056/NEJMoa1010331 (2011).
8. Garcon, N., Vaughn, D. W. and Didierlaurent, A. M. Development and evaluation of AS03, an Adjuvant System containing alphatocopherol and squalene in an oil-in-water emulsion. Expert Review of Vaccines 11, 349-366, doi:10.1586/erv.11.192 (2012).
9. Garcon, N. et al. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 25, 217-226, doi:10.2165/11591760-000000000-00000 (2011).
10. Duthie, M. S., Windish, H. P., Fox, C. B. and Reed, S. G. Use of defined TLR ligands as adjuvants within human vaccines. Immunological Reviews 239, 178-196, doi:10.1111/j.1600-065X.2010.00978.x (2011).
11. Kong, N. C. et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney International 73, 856-862, doi:10.1038/sj.ki.5002725 (2008).
12. Wu, T. Y. et al. Rational design of small molecules as vaccine adjuvants. Science Translational Medicine 6, 263ra160, doi:10.1126/scitranslmed.3009980 (2014).
13. Levy, J. et al. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial. Human Vaccines and Immunotherapeutics 11, 620-631, doi:10.1080/21645515.2015.1 011021 (2015).
14. Hellenbrand, W. et al. Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine. The Journal of Infection 66, 48-56, doi:10.1016/j.jinf.2012.09.008 (2013).
15. Finkelman, F. D. et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annual Review of Immunology 8, 303-333, doi:10.1146/annurev.iy.08.040190.001511 (1990).
16. Iavarone, C. et al. A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding. Journal of Immunology 186, 4213-4222, doi:10.4049/jimmunol.1003585 (2011).
17. Sogaard, O. S. et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clinical Infectious Diseases: An Official Publication of The Infectious Diseases Society of America 51, 42-50, doi:10.1086/653112 (2010).
18. OHagan, D. T. and Valiante, N. M. Recent advances in the discovery and delivery of vaccine adjuvants. Nature Reviews. Drug discovery 2, 727-735, doi:10.1038/nrd1176 (2003).
19. Didierlaurent, A. M. et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. Journal of Immunology 183, 6186-6197, doi:10.4049/jimmunol.0901474 (2009).
20. Mbow, M. L., De Gregorio, E. and Ulmer, J. B. Alums adjuvant action: grease is the word. Nature Medicine 17, 415-416, doi:10.1038/nm0411-415 (2011).
21. Mancini, F. et al. One Dose of Staphylococcus aureus 4C-Staph Vaccine Formulated with a Novel TLR7-Dependent Adjuvant Rapidly Protects Mice through Antibodies, Effector CD4+ T Cells, and IL-17A. PloS One 11, e0147767, doi:10.1371/journal. pone.0147767 (2016).
22. Isailovic, N., Daigo, K., Mantovani, A. and Selmi, C. Interleukin-17 and innate immunity in infections and chronic inflammation. Journal of Autoimmunity 60, 1-11, doi:10.1016/j.jaut.2015.04.006 (2015).
23. Levy, O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nature Reviews. Immunology 7, 379-390, doi:10.1038/nri2075 (2007).
24. Kollmann, T. R., Levy, O., Montgomery, R. R. and Goriely, S. Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity 37, 771-783, doi:10.1016/j.immuni.2012.10.014 (2012).
25. Dagan, R., Poolman, J. and Siegrist, C. A. Glycoconjugate vaccines and immune interference: A review. Vaccine 28, 5513-5523, doi:10.1016/j.vaccine.2010.06.026 (2010).